Coya Therapeutics (NASDAQ:COYA) Receives Buy Rating from BTIG Research

Key Points

• BTIG Research has reiterated a "buy" rating for Coya Therapeutics (NASDAQ:COYA) with a price target of $15.00, suggesting a potential upside of 165.02% from its current stock price.
• A total of five research analysts have assigned a "buy" rating to Coya Therapeutics, with an average consensus price target of $16.20.
• Coya Therapeutics recently reported a quarterly loss of ($0.36) EPS, missing estimates, and had revenues of $0.16 million compared to expectations of $0.78 million.

Coya Therapeutics (NASDAQ:COYA - Get Free Report)'s stock had its "buy" rating restated by BTIG Research in a report issued on Tuesday,Benzinga reports. They currently have a $15.00 price objective on the stock. BTIG Research's target price would indicate a potential upside of 165.02% from the stock's current price.

COYA has been the subject of a number of other reports. Lake Street Capital assumed coverage on Coya Therapeutics in a research note on Wednesday, July 9th. They issued a "buy" rating and a $16.00 target price for the company. D. Boral Capital reaffirmed a "buy" rating and issued a $18.00 target price on shares of Coya Therapeutics in a research note on Monday. HC Wainwright reaffirmed a "buy" rating and issued a $18.00 target price on shares of Coya Therapeutics in a research note on Monday, August 25th. Finally, Chardan Capital reaffirmed a "buy" rating and issued a $14.00 target price on shares of Coya Therapeutics in a research note on Wednesday, September 17th. Five research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $16.20.

Coya Therapeutics Stock Performance

Shares of COYA opened at $5.66 on Tuesday. Coya Therapeutics has a one year low of $4.65 and a one year high of $10.24. The stock has a market capitalization of $94.66 million, a price-to-earnings ratio of -4.56 and a beta of 0.26. The stock has a 50 day moving average price of $6.13 and a 200 day moving average price of $5.98.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.14). The company had revenue of $0.16 million during the quarter, compared to analysts' expectations of $0.78 million. On average, analysts predict that Coya Therapeutics will post -1.15 earnings per share for the current year.

Hedge Funds Weigh In On Coya Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of COYA. Charles Schwab Investment Management Inc. acquired a new stake in Coya Therapeutics in the 1st quarter valued at about $65,000. Jane Street Group LLC acquired a new stake in shares of Coya Therapeutics during the 4th quarter worth about $74,000. Northwestern Mutual Wealth Management Co. acquired a new position in Coya Therapeutics during the second quarter worth approximately $119,000. Northern Trust Corp increased its position in Coya Therapeutics by 12.2% during the fourth quarter. Northern Trust Corp now owns 28,549 shares of the company's stock worth $164,000 after buying an additional 3,099 shares during the period. Finally, Dauntless Investment Group LLC purchased a new position in shares of Coya Therapeutics in the 1st quarter valued at approximately $1,083,000. 39.75% of the stock is currently owned by hedge funds and other institutional investors.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.